News

Medical Device Sales - Macon, GA

POSITION SUMMARY







Accountable for selling, promoting, and delivering a portfolio of products and services to accounts in targeted market segments, and contributing to CCS Medical sales and profit goals. The Account Executive operates with general supervision within an assigned geographic territory.







ESSENTIAL DUTIES AND RESPONSIBILITIES






· Maintains and grows business within an assigned territory by developing an effective planning process (a business plan) and maintaining complete records of all high volume accounts, which include focused self-test markets and top-decile healthcare providers



· Acts to meet/exceed customer expectations by sustaining regular contact and building superior relationships with key healthcare decision-makers and influencers



· Promotes customer brand loyalty by participating in or joining regional or local diabetes professional organizations that serve health care providers and or consumers



· Demonstrates competency in the company’s products and services by managing the entire sales process, presenting (oral and written) all aspects of the company products, maintaining working knowledge of existing marketing programs



· Builds CCS Medical image as a leader in providing medical supplies by engaging in promotional activities and by attending conventions, meetings, and symposiums, as assigned or directed



· Practices expense control by keeping within a defined budget and managing given resources



· Competently communicates on a daily basis using all mediums available – phone-mail, e-mail, etc. in order to adequately report data on the industry, territory, market trends, promotion and competitive activity



· Primary sales focus involves gaining the recommendation of medical providers (e.g. Physicians, Nurses, third-party payer personnel, etc.); a secondary emphasis is assuring patient or consumer access to the product or services through the services of CCS Medical; a third responsibility is to work closely with all manufacturer sales reps to develop key targets and build customer base



· Maintains and inputs sales territory records and to complete sales data and promotional information







OTHER RESPONSIBILITIES







· Must be self-motivated, organized, personable, and possess excellent communication skills to prioritize activities with targeted high volume accounts and to interact with manufacturer reps and management.



· Must be current in their knowledge of all products, services, and marketing programs within CCS Medical



· Must maintain a working knowledge of diabetes health care market, industry/customer buying processes, competitive product and selling information



· Required to develop/possess the ability to prioritize sales activities needed to best drive the business in their geographic territory



· Maintains and promotes patient confidentiality



· Maintains open lines of communication with Administration, department management and other departmental personnel



· Follows all Medicare, Medicaid and Private Insurance regulations and requirements



· Actively participates in Continuous Quality Improvement



· Demonstrates thoroughness with all work related activities. Strives to continually improve quality and productivity results displayed by Department Personnel on an ongoing basis



· Assumes other duties and responsibilities as assigned by manager



· Maintains scheduling flexibility to ensure availability to meet the needs of the department for all hours of operation and maintains regular and consistent attendance



· Abides by all policies, procedures and protocols set forth in the departmental, CCS Medical Personnel and Administrative Policy Manuals.



· Is compliant with all CCS Medical safety policies and protocols, completes all necessary safety training, and obeys all traffic rules and signs.







Note: The above statements describe the general nature and level of the work being performed and are not an exhaustive list of all responsibilities of an employee in this job. Job duties can change at any time as directed by management. Furthermore, they do not establish a contract for employment and are subject to change at the discretion of the employer.











PRIMARY CUSTOMERS






Internal: Department Managers, Business Development employees



External: Health Care Medical Provider, Physicians (Primary Care, Internist, Endocrinologist and Diabetologist), Physician Assistants, Nursing personnel (office, private industry, managed care, hospital setting), Nurse Specialty groups (Diabetes educators, Nurse Practitioners), Registered Dieticians, diagnostics manufacturers







KNOWLEDGE SKILLS AND ABILITIES REQUIRED







· Bachelor’s Degree (BA) from a four-year college or university and three years of Sales experience or the equivalent combination of education and/or experience. Two or more years of outside sales experience is preferred.



· Ability to read, analyze and interpret general business periodicals, professional journals, technical procedures or government regulations; ability to write reports, business correspondence, and procedure manuals; ability to effectively present information and respond to questions from groups of managers, clients, customers and the general public



· Excellent communication and interpersonal skills are required when dealing with customers, fellow employees, and management







DESIRED KEY COMPETENCIES







· Must be organized, self-motivated, and possess basic business knowledge (e.g. sales, marketing, finance) to meet/exceed sales objectives



· Quick learner to address customer questions or objectives based on technical knowledge of the product or disease state



· Proficient with various Microsoft Office software such as Word, Excel and PowerPoint



· Strong planning, organization and execution skills



· Strong impact and influence



· Strong interpersonal skills



· Resource Allocation



· Information Management



· Facilitation/Presentation Skills



· Learning Orientation



· Judgement and Decision Making



· Teamwork and Team Leadership











Employees enjoy great health, dental, and disability insurance benefits (large portion of premiums paid by the company), including a 401K plan with company match and vesting schedule, plus paid time off within the first year. EEO/DFWP.

If your experience meets the requirements listed above, and you would like to be considered for this position, please forward your resume to CCS Medical at salesjobs@ccsmed.com .
 






Medical Sales Specialist

CCS Medical is a nationally known healthcare company providing wound care products to patients with chronic, non-healing wounds. For healthcare professionals and their patients – including tens of thousands of seniors on Medicare – the healthcare partners at CCS Medical are a life line for information, support, and reliability, aiding in the patient’s wound healing.

Due to continued growth, CCS Medical is seeking to add experienced onsite Medical Sales Specialist in Chapel Hill, NC. Here's your opportunity to become part of CCS Medical, a $400 million national medical supplier of wound care and diabetes products that will reward your efforts with a competitive salary, open ended commission program, and generous benefits.

POSITION SUMMARY



The Medical Sales Specialist is responsible for implementing and coordinating the On-Site Supply Delivery System service for patients who choose CCS Medical as their supplier and to maximize outside marketing in their assigned territory. The MSS offers products that provide improved healing outcomes, reduce the clinics supply costs, while simultaneously providing the profit margin for CCS Medical to support this on-site position

ESSENTIAL DUTIES AND RESPONSIBILITIES

Ø Achieve or exceed the assigned monthly sales target.

Ø Maintain all original documentation at the Wound Care Clinic in an organized manner.

Ø Track, account, and manage the CCS Medical on-site inventory.

Ø Manage the order cycle process.

Ø Prepare and analyze reports.

Ø Introduce CCS Medicals services to every patient visiting the Wound Care Clinic.

Ø Educate CCS Medicals patient customers regarding the proper use of the products provided.

Ø Be a resource for the Wound Care Clinic staff and patients regarding supplies and Medicare coverage questions.

Ø In-service the Wound Care Clinic staff regarding supplies stocked in CCS Medicals on-site inventory as well as the new products that become available.

Ø Be readily available during all productive Wound Care Clinic hours.

Ø Attend and participate in clinic meetings where CCS Medical and DME issues are of direct concern.

Ø Create awareness with the Wound Care Clinic staff and physicians regarding CCS’ service.



DME or HME experience is a plus.



Minimum qualifications/requirements for this position are:


* Must have 2+ years sales experience, with proven track record

* Ability to work independent of direct supervision
* Superior verbal and written communication skills
* Must be a self-starter focused on personal accountability of achieving sales goals
* Basic Computer knowledge

* HS Diploma or equivalent

* Clean driving record



Comprehensive benefit package includes:

ü Company subsidized Medical, Dental, & Vision benefits

ü 401(k) with generous company match & vesting schedule

ü Flexible spending accounts (Health Care & Dependent Day Care)

ü Paid time off within your first year

ü Excellent promotional opportunities



Thank you for your interest in career opportunity with CCS Medical.
 






Healthcare Account Executive - Surgical
Functional Area Sales & Service
Division Healthcare
Location Washington-Seattle
Country United States
Employment Status Full Time
Job Description You’ll promote the Ecolab – Microtek Medical’s innovative product solutions for risk reduction and protection in clinical environments around the world. As a leading manufacturer of infection & fluid control disposable medical products, our goal is to provide healthcare professionals with innovative product solutions that encompass a high-level of patient care & prevention of cross contamination in a variety of clinical settings including operating rooms, interventional radiology, ultrasound, cardiac catheterization labs & ambulatory surgical centers worldwide. Make your expertise work for you with Ecolab – Microtek Medical, the solution is you.

This position reports to the Regional Sales Manager.

Main Responsibilities:



Introduce new offerings to existing customers & prospect/cold call/network to obtain new business.

Manage customer base & build relationships through professional demeanor & strong interpersonal skills.

Make presentations on product portfolio and handle inquiries on commercial aspects of product, pricing & company policies.

Provide outstanding customer service, educating customers during the sales process & responding to complaints, while being accommodating to their needs.

Participate in regional/national sales training.




Cities included in Market: Seattle, WA and Portland, OR Metro Areas

Area where candidate must reside: Seattle, WA


Basic Qualifications:



A Bachelor’s degree

A minimum of 2 years medical / healthcare sales experience, with experience selling into the hospital environment.

A valid driver's license and acceptable motor vehicle record (2 years)

No immigration sponsorship offered for this role


Preferred Qualifications:



Surgical and/or medical disposables sales experience strongly preferred

Demonstrated relationship management, consulting, negotiation & presentation skills

Existing healthcare / hospital contacts within assigned territory

Customer service skills with the ability to problem solve & devise customer solutions

Ability to read, analyze & interpret scientific & technical information

Self motivated with effective organizational & time management skills
 






Sales Rep - RPU - Winchester, VA-WIN00000102
Description

UCB, Inc is seeking a talented sales person for our Respiratory/Pediatric division in Winchester, VA. Our Sales Reps market our line of prescription products to doctors, hospitals, pharmacies, and managed care organizations in their assigned territories nationwide. Additionally, representatives are responsible for:
Updating and maintaining customer information in their computer databases.
Completing monthly expense reports.
Coordinating and organizing luncheons, seminars, and other special events for customers.
Communicating and cooperating w/ co-promotion counterparts in the territory.
Organizing and keeping track of a sample inventory.
Attending meetings and training sessions as required.
Qualifications
To Qualify:

BA/BS degree or the equivalent work experience in the Pharmaceutical industry preferred.
Minimum of 1-2 year(s) of outside, business to business sales experience, again preferrably pharmaceutical.
No more than two moving violations in the last three yrs. No DUI or reckless driving in last five years. (Must be insurable for company car).
Must be able to learn technical medical information.
Ability to communicate effectively and professionally w/ medical professionals.
Must be able to work independently; a self-starter.
Ability to travel, as required, to meetings and training sessions.
Job Sales
Primary LocationUnited States-VA-Winchester
Schedule Full-time
Job Level Individual Contributor
Education Level Bachelor's Degree
Job Type Standard
Shift Day Job
Employee Status Regular
Travel Yes, 75% of the time
 






MEDICAL SALES REP

Job Information
Post Date: Oct 23, 2009 Type: Full time
Base Salary : $70,000+ Total Income Potential: $110,000 to $150,000
Location: US - Pennsylvania - PHILADELPHIA Job Reference: PAQQMed
Job Zip Code: - n/a -

APPLY FOR THIS JOB


Job Details
Description
Our client, a leading medical information company is seeking a top performer for a high profile sales position in Pennsylvania(PA).


Skills
Qualified Candidates should possess:
** 2+ years of medical sales experience.
** BA/BS degree
** Documented track record of successes
** Clean Driving Record



Contact Details / Apply for this Job
Contact Information
Bradin Search Group, Inc.

State/Province: New Jersey
Country: United States
Email/URL: jobs@bradinsearch.com
 






United Medical Systems, headquartered in Westborough, MA, is a rapidly-expanding company in the field of shared mobile medical services. We currently have accounts in approximately 36 states. Our focus is in transportable lithotripsy and stereotactic breast biopsy services.

If you are seeking a new challenge that offers independent responsibility, we may have the right opportunity for you.

•Paid licensing and continuing education
•Company paid expenses
•Competitive compensation and benefits package to include bonus incentives
•A great team environment
 






EXPERIENCED companies can get Medicare reimbursement.

Medicare Reverses Billing Change On Genentech Drug
By The Associated Press 10/28/09 - 01:25 PM EDT Loading Comments... Add Comment

MATTHEW PERRONE
WASHINGTON (AP) — Medicare officials are backing off a policy that pushed many doctors to use a $2,000 injectable drug for a potentially blinding eye disorder, over a similar treatment that costs about $50. The Centers for Medicare and Medicaid Services said late Tuesday it will reverse a decision from earlier this month that cut reimbursement for Avastin, a biotech drug from Genentech.
The payment change had the effect of forcing doctors to use a similar Genentech drug called Lucentis, which costs about $2,000 per injection.
Lucentis is formally approved for eye care, but it acts on the same biological protein as Avastin, which is approved as a cancer drug. For years, eye doctors have used tiny amounts of Avastin and billed the government for the cost, rather than purchasing Lucentis.
That practice largely stopped after an Oct. 1 change slashed Medicare reimbursement for Avastin to $7 from about $50, making it difficult to recoup the cost of the drug. Eye doctor groups complained the policy forced them to buy Lucentis instead, since the drug was still reimbursed at the full cost.

A spokesman for the Centers for Medicare and Medicaid Services said in a statement Tuesday evening that doctors will be able to resume billing for small doses of Avastin beginning in 2010.
Sen. Herb Kohl, D-Wis., praised the reversal Wednesday, saying it would save money for both the government and seniors. "I'm pleased that CMS heeded the concerns of the medical eye care community and the aging committee," said Kohl, who chairs the Special Committee on Aging. "Even seniors who have insurance often cannot afford the high co-payments associated with Lucentis."
The co-payment for Lucentis averages $400 per injection, versus $9 for Avastin, according to the American Academy of Ophthalmologists.
An academy spokesman said Wednesday the group is "extremely pleased" with CMS' decision.
Kohl sent a letter to CMS earlier this month questioning the rationale behind the change. CMS runs the Medicare and Medicaid programs, which provide health care coverage to the elderly, poor and disabled.
A spokeswoman for South San Francisco-based Genentech said the company had no role in the decision to adjust the payment rate.

"Genentech believes that people should have access to the medicines their doctors feel are most appropriate for them," said Megan Pace.
The federal government spends about $1 billion a year on Lucentis, which is approved to treat wet, macular degeneration, a condition that causes blood vessels in the eye to leak fluid. Genentech, a unit of Swiss firm Roche, says Lucentis is specially formulated with smaller molecules than Avastin to better penetrate the eye.
However, many eye doctors say there is no detectable difference in outcomes for patients. The American Academy of Ophthalmologists estimates about 60 percent of all injections for macular degeneration use Avastin.
Genentech has previously said Lucentis' price reflects the cost of developing the drug, which included a clinical trial involving more than 6,000 patients at a cost of more than $45,000 a patient.
 






GTC cuts 45 workers, lines up retention bonuses for execsBoston Business Journal - by Julie M. Donnelly and Craig M. Douglas
Struggling drug developer GTC Biotherapeutics Inc. plans to cut 45 employees, or a third of its entire workforce.

Meanwhile, GTC has lined up $270,000 in “retention” payments for its senior executive team if the individuals stay with the cash-strapped company beyond March 31. The cash payments also kick in if the executives in question are terminated before that date.

The named executives and potential retention payments are as follows:

Chairman and CEO Geoffrey F. Cox stands to receive $94,000
Chief Financial Officer John B. Green stands to receive $44,000
Harry M. Meade, head of GTC’s research and development, stands to receive $44,000
Richard Scotland, head of regulatory affairs, stands to receive $44,000
Daniel S. Woloshen, the company’s general counselstands to receive $44,000

GTC employed 154 people before Monday’s announced cuts. CEO Cox said in a statement that the move would save the company between $5 million and $6 million annually.

On Nov. 6, GTC said it will likely run out of cash before March 1 unless new revenue or financing opportunities arise before then. The Framingham, Mass.-based developer of drug therapies derived from animal proteins recently closed a $10 million financing round with LFB Biotechnologies that brought its total cash position to around $11.8 million.

GTC booked $749,000 in revenue in the third quarter, down from the $2.9 million generated a year earlier. The company’s net loss for the quarter was $5.1 million, compared with $6.1 million in 2008’s corresponding period.
--------------
Why don't WE get retention bonuses?
 






GTC cuts 45 workers, lines up retention bonuses for execsBoston Business Journal - by Julie M. Donnelly and Craig M. Douglas
Struggling drug developer GTC Biotherapeutics Inc. plans to cut 45 employees, or a third of its entire workforce.

Meanwhile, GTC has lined up $270,000 in “retention” payments for its senior executive team if the individuals stay with the cash-strapped company beyond March 31. The cash payments also kick in if the executives in question are terminated before that date.

The named executives and potential retention payments are as follows:

Chairman and CEO Geoffrey F. Cox stands to receive $94,000
Chief Financial Officer John B. Green stands to receive $44,000
Harry M. Meade, head of GTC’s research and development, stands to receive $44,000
Richard Scotland, head of regulatory affairs, stands to receive $44,000
Daniel S. Woloshen, the company’s general counselstands to receive $44,000

GTC employed 154 people before Monday’s announced cuts. CEO Cox said in a statement that the move would save the company between $5 million and $6 million annually.

On Nov. 6, GTC said it will likely run out of cash before March 1 unless new revenue or financing opportunities arise before then. The Framingham, Mass.-based developer of drug therapies derived from animal proteins recently closed a $10 million financing round with LFB Biotechnologies that brought its total cash position to around $11.8 million.

GTC booked $749,000 in revenue in the third quarter, down from the $2.9 million generated a year earlier. The company’s net loss for the quarter was $5.1 million, compared with $6.1 million in 2008’s corresponding period.
--------------
Why don't WE get retention bonuses?
They don't care if we leave. Look at how they are treating the IMRs.
 






http://finance.yahoo.com/news/Uroplasty-Reports-Results-For-prnews-789025613.html?x=0&.v=1


Our fiscal third quarter sales illustrate the continued strong growth of Macroplastique in the U.S.," continued Mr. Kaysen. "Sales of our Macroplastique product in the U.S. through nine months of our current fiscal year have about doubled over the corresponding year-ago period. However, our European sales of Macroplastique continue to be impacted by a competitive product launch. Urgent PC sales in the U.S. remain challenged by the uncertain insurance reimbursement environment, but have remained relatively stable in recent quarters. At the same time, with our vigilant efforts to control expenses, we have maintained our December 31, 2009 cash position at about the same level as at September 30, 2009. We believe we have adequate liquidity to meet our needs for the next 12 months."

---------
What does "adequate liquidity" mean?
 


















Urgent PC on TV - Re: News

.Uroplasty's Urgent(R) PC System to be Featured on National Television Program 'The Doctors'

Buzz up! 0 Print..Companies:Uroplasty Inc..Related Quotes
Symbol Price Change
UPI 3.03 +0.07


{"s" : "upi","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""} Press Release Source: Uroplasty, Inc. On Thursday April 8, 2010, 6:30 am EDT
MINNEAPOLIS, April 8 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (NYSE Amex: UPI), a medical device company developing, manufacturing and marketing innovative proprietary products to treat voiding dysfunctions, today announced that Monday, April 12, the company's Urgent® PC Neuromodulation System is expected to be featured in a segment of the popular television program "The Doctors."

The Urgent PC System is a proprietary, minimally invasive, percutaneous tibial nerve stimulation (PTNS) device designed for office-based treatment of urinary urgency, frequency and urge incontinence, symptoms often associated with overactive bladder (OAB). Local listings and times, which vary, are available through the following link: http://bit.ly/UrgentPConTV.

"Overactive bladder is an important health issue for women and it will be valuable for viewers to learn from 'The Doctors' – a prominent, nationally-syndicated TV program on health issues – about treatment options such as our Urgent PC System," said David Kaysen, President and CEO of Uroplasty. "OAB is a chronic condition affecting approximately 33 million adults in the United States and more attention needs to be paid to it and the spectrum of treatment options that can help patients."

"'The Doctors' program is expected to feature Dr. Kiarash Michel of Comprehensive Urology Medical Group in Los Angeles, a physician currently using Urgent PC," said Mr. Kaysen. "Dr. Michel and one of his patients will discuss the problems she faced prior to treatment, the treatment experience with Urgent PC and her improvement afterward. This adds to attention brought to Urgent PC from previous mentions on local news programs. But this is the first appearance on a nationally syndicated program which is aimed directly at the main demographic population of potential patients who could benefit from Urgent PC therapy."

For more information about the Urgent PC Neuromodulation System, please call (866) 277-0466 or visit http://www.uroplasty.com/.

About the Urgent PC Neuromodulation System

The Urgent PC Neuromodulation System is a proprietary, minimally invasive nerve stimulation device designed for office-based treatment of urge incontinence, urinary urgency and urinary frequency, symptoms often associated with overactive bladder. Application of neuromodulation therapy targets specific nerve tissue and disrupts the signals that lead to these symptoms. Uroplasty sells the Urgent PC system in the United States, Canada, and countries recognizing the CE mark. Outside of the United States, Urgent PC is also indicated for the treatment of fecal incontinence.
 












Yahoo

8:42AM Uroplasty confirms that PTNS will receive a category 1 CPT reimbursement code (UPI) 3.99 : Co was informed that percutaneous tibial nerve stimulation (PTNS), the procedure performed using the Uroplasty Urgent PC Neuromodulation System, will receive a category 1 CPT reimbursement code. This is expected to occur in October 2010. Reimbursement rates for the procedure have not yet been established and the new CPT code may not be submitted prior to January 2011.
 






CODE news

Percutaneous Tibial Nerve Stimulation Using the Urgent(R) PC Neuromodulation System to be Assigned a Category 1 CPT Code

Press Release Source: Uroplasty, Inc. On Thursday May 6, 2010, 6:30 am EDT
MINNEAPOLIS, May 6 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (NYSE Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, announced today that it has been informed that percutaneous tibial nerve stimulation (PTNS), the procedure performed using the Uroplasty Urgent PC Neuromodulation System, will receive a category 1 CPT reimbursement code. This is expected to occur when those codes are published by the Centers for Medicare and Medicaid Services, which is expected in October 2010.

Reimbursement rates for the procedure have not yet been established, the new CPT code number has not been assigned, and reimbursement requests using the new CPT code may not be submitted prior to January 2011. Further, the code will not ensure that additional reimbursement agencies beyond those that currently cover the procedure, whether governmental agencies or private payers, will cover PTNS treatments.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the continued commercialization of our Urgent PC System, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence - symptoms often associated with overactive bladder. We also offer Macroplastique®, an injectable bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. Please visit Uroplasty, Inc. at http://uroplasty.com.
 






Uroplasty Reports Financial Results for the Second Quarter FY2011
Global sales increase 9%; U.S. Macroplastique sales grow 50%
Sales to U.S. customers up 23%
Conference call today at 3:30 p.m. CT


Share
retweet
EmailPrint..Companies:Uroplasty Inc..Related Quotes
Symbol Price Change
UPI 4.4101 -0.0699


{"s" : "upi","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""} Press Release Source: Uroplasty, Inc. On Wednesday October 27, 2010, 4:02 pm EDT
MINNEAPOLIS, Oct. 27 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Nasdaq:UPI - News), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the second fiscal quarter ended September 30, 2010. Global sales grew 9% driven primarily by a 50% increase in Macroplastique product sales in the U.S.

"We reported a 9% increase in revenue in the seasonally weakest quarter of the year, while making substantial progress in positioning the Company for the relaunch of Urgent PC with the availability of the new CPT code early next year," said David Kaysen, President & CEO of Uroplasty, Inc. "Growth in sales to U.S. customers of 23% was driven by our renewed focus on Macroplastique, as well as an increase in sales of Urgent PC. Sales outside the U.S., excluding currency translations, were up 4% from the same quarter the prior year."

"Late in our fiscal second quarter, we announced that five regional Medicare carriers planned to initiate coverage and payment for Posterior Tibial Nerve Stimulation (PTNS), using our Urgent PC system. Given the time the carriers require to implement this coverage, including the programming of computers to accept electronic claims, as well as the desire on the part of physicians to start slowly with submitting claims to insure payment, we saw little revenue contribution from this development for the period.

"In anticipation of the establishment of a new CPT code and reimbursement rates for the Urgent PC procedure, we are moving forward on our plan to build our sales force and complete the training and other efforts necessary to drive awareness and sales of Urgent PC. We have doubled the number of sales reps from 15 at the start of our fiscal year to 30, who have either officially joined Uroplasty or have accepted positions with the company and are scheduled to be on board by early November. We have also added three field reimbursement specialists and are looking for a fourth. With the four field sales managers already in place, we are well on our way to building the sales organization we believe we need to execute a successful marketing effort for Urgent PC. We anticipate that the new CPT code number and reimbursement rates will be assigned and published in the Federal Register by the Centers for Medical and Medical Services (CMS) very shortly and we want to be well-positioned to move forward as quickly as possible to educate physicians and consumers about the benefits of our procedure," Mr. Kaysen added.

Fiscal Second Quarter and First Half Results for the Period Ended September 30, 2010

Net sales for the three months ended September 30, 2010 totaled $3.2 million, an increase of 9% over net sales of $3.0 million for the same quarter of the prior fiscal year. Excluding the translation impact of foreign currency exchange rates, sales increased by approximately 13%. For the six months ended September 30, 2010, net sales were $6.3 million, 8% above net sales for the comparable period of 2009 of $5.8 million. Excluding the impact of foreign exchange translation, sales grew by 12%.

Sales to customers in the U.S. for the three months ended September 30, 2010 were $1.8 million, a 23% increase compared to $1.5 million in net sales for the year-ago quarter. During the first half of fiscal 2011, sales to customers in the U.S. totaled $3.5 million, representing a 17% increase over net sales of $3.0 million for the six month period of fiscal 2010.

Sales in the U.S. of the Urgent PC product for the three months ended September 30, 2010 increased 6% to $1.0 million compared with $960,000 for the same period last year. This was at the high end of the recent range of quarterly sales between $900,000 and $1.0 million. For the recent six month period, sales from Urgent PC totaled $1.9 million, a decline of 3% from $2.0 million for the comparable period last year.

Sales in the U.S. of Macroplastique increased 50% to $791,000 for the three months ended September 30, 2010, from $528,000 for the same period last year. For the six months of fiscal 2011, sales of Macroplastique increased 58% to $1.5 million versus $949,000 in the same period a year ago. The growth in Macroplastique product sales reflects the increased sales and marketing focus on this product line as well as competitive benefits that have been highlighted by independent reviews.

Net sales to customers outside of the U.S. for the three months ended September 30, 2010 were $1.4 million, a decrease of 6% from $1.5 million in the same quarter last year. Excluding the impact of foreign exchange translation, sales increased by approximately 4%. For the six months ended September 30, 2010, sales of $2.8 million were roughly unchanged from the comparable period of the prior year. Excluding the impact of foreign exchange translation, sales increased by approximately 7%.

The operating loss for the fiscal second quarter ended September 30, 2010 was $947,000 compared with $877,000 in the prior year. The operating loss, excluding non-cash charges for share-based compensation and depreciation and amortization, of $591,000 in the recent second quarter increased from approximately $475,000 in the year-ago quarter, primarily due to increased spending because of higher bonuses, commissions, increase in headcount and consulting expenses. The net loss for the three months ended September 30, 2010 was $923,000, or $0.05 per diluted share, as compared to a net loss of $875,000, or $0.06 per diluted share, for the quarter ended September 30, 2009.

Cash and cash equivalents and short-term investments at September 30, 2010 totaled $21.4 million. Reflected in the total was the contribution from the proceeds of a recently completed public offering of common shares. In July 2010, the company issued 4.6 million shares at $3.50 per share, for net proceeds of approximately $14.9 million. The company plans to use the proceeds to expand the U.S. sales and marketing organizations to support the Urgent PC business, and for clinical studies, working capital and general corporate purposes. Following completion of the public offering, the company has 20.5 million common shares outstanding.

"With the additional capital raised through the offering, we have the funds necessary to execute our plan to drive sales growth and move toward profitability," continued Mr. Kaysen. "While we are managing this cash very carefully, over the next couple of quarters, we expect to increase our investments in building our marketing and sales effort in support of our relaunch of Urgent PC. In addition, we intend to explore the emerging opportunity in the U.S. to treat fecal incontinence using the Urgent PC, which has already received a CE Mark for treatment of fecal incontinence in Europe. With the opportunities ahead for Urgent PC and the momentum in Macroplastique sales supported by a strong balance sheet, we are excited about the outlook for the company."
 






"Late in our fiscal second quarter, we announced that five regional Medicare carriers planned to initiate coverage and payment for Posterior Tibial Nerve Stimulation (PTNS), using our Urgent PC system. Given the time the carriers require to implement this coverage, including the programming of computers to accept electronic claims, as well as the desire on the part of physicians to start slowly with submitting claims to insure payment, we saw little revenue contribution from this development for the period."

Du huh. Why were you on everyone's ass to fill out a report to give a weekly update if you KNEW this was happening?
 






"With the additional capital raised through the offering, we have the funds necessary to execute our plan to drive sales growth and move toward profitability," continued Mr. Kaysen. "While we are managing this cash very carefully, over the next couple of quarters, we expect to increase our investments in building our marketing and sales effort in support of our relaunch of Urgent PC. In addition, we intend to explore the emerging opportunity in the U.S. to treat fecal incontinence using the Urgent PC, which has already received a CE Mark for treatment of fecal incontinence in Europe. With the opportunities ahead for Urgent PC and the momentum in Macroplastique sales supported by a strong balance sheet, we are excited about the outlook for the company."

Are they going to sell Macroplastique in order to pay for the Fecal Incontinence clinical trial?
 






Re: CODE news

Percutaneous Tibial Nerve Stimulation Using the Urgent(R) PC Neuromodulation System to be Assigned a Category 1 CPT Code

Press Release Source: Uroplasty, Inc. On Thursday May 6, 2010, 6:30 am EDT
MINNEAPOLIS, May 6 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (NYSE Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, announced today that it has been informed that percutaneous tibial nerve stimulation (PTNS), the procedure performed using the Uroplasty Urgent PC Neuromodulation System, will receive a category 1 CPT reimbursement code. This is expected to occur when those codes are published by the Centers for Medicare and Medicaid Services, which is expected in October 2010.

Reimbursement rates for the procedure have not yet been established, the new CPT code number has not been assigned, and reimbursement requests using the new CPT code may not be submitted prior to January 2011. Further, the code will not ensure that additional reimbursement agencies beyond those that currently cover the procedure, whether governmental agencies or private payers, will cover PTNS treatments.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the continued commercialization of our Urgent PC System, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence - symptoms often associated with overactive bladder. We also offer Macroplastique®, an injectable bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. Please visit Uroplasty, Inc. at http://uroplasty.com.

Uroplasty announced CMS published anticipated Category I CPT code for Posterior Tibial Nerve Stimulation (UPI) 4.41 : Co announced that the Centers for Medicare and Medicaid Services (CMS) has published, in the November, 2010 Federal Register, the anticipated Category I CPT code for Posterior Tibial Nerve Stimulation (PTNS). Uroplasty's Urgent PC Neuromodulation System is used to provide PTNS and effective January 1, 2011, this procedure will now be billed under the new CPT code 64566, with the descriptor "Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes programming." The publication also indicated that the "relative value units" (RVUs) assigned to the new CPT code for PTNS will be 3.82... Based upon the newly published CF of $25.52 per RVU, which is also in this edition of the Federal Register, the base Medicare physician payment for PTNS will be ~$97.49 per procedure. The CF may vary throughout 2011 as a result of Congressional action or CMS rule changes. Furthermore, the Company anticipates private-pay insurance companies, as is typically the case, to reimburse a higher amount.